Home › Eli Lilly And Company And Boehringer Ingelheim Announce New Drug Application Filing In The U.S. For New Insulin Glargine Product
 

Keywords :   


Eli Lilly And Company And Boehringer Ingelheim Announce New Drug Application Filing In The U.S. For New Insulin Glargine Product

2013-12-23 00:57:30| drugdiscoveryonline News Articles

Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an investigational basal (long-acting) insulin

Tags: us new company product

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05'Time running out' plea over shipyard's future
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05China's Nio unveils Tesla Model Y rival
16.05Could the US economy be doing too well?
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
More »